Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,longTermDebt,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,priceHint,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,shortName,marketState,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,IMGN,94120000.0,199942000,,,-34051000,,-34051000,10209000,-18707000,-28916000,-28916000,,-4668000,,,,0,15706000,44622000,34413000,-5135000,,-34051000,-34051000,1458012000.0,251842000.0,94120000.0,80522000.0,345962000.0,1999000.0,-1365891000.0,99611000.0,7325000.0,283120000.0,134353000.0,2096000.0,19065000.0,319572000.0,21031000.0,12916000.0,,3730000.0,-893000.0,34778000.0,-2321000.0,34778000.0,-10736000.0,-44621000.0,551000.0,-5452000.0,-7078000.0,-893000.0,,185219000.0,en-US,US,EQUITY,True,Delayed Quote,USD,2,NMS,6.18,1630526402,0.12999964,6.04,6.28,5.995,2922641,0,"ImmunoGen, Inc.",PRE,us_market,2.1487544,5.995 - 6.28,6.05,0.0,0.0,40,40,finmb_29794,NasdaqGS,"ImmunoGen, Inc.",USD,1515862,1404971,2.7999997,0.8284023,3.38 - 10.88,-4.7000003,-0.43198532,3.38,10.88,1620649800,1636029000,1636374600,0.09958824,7.0028987,-0.82289886,-0.11750832,-7.6296296,-0.268,-0.81,-0.72,-8.583333,0.471,5.6202855,0.5597143,1235641472,13.121019,15,America/New_York,EDT,-14400000,False,False,1.35,,,10.88,3.38,5.62,7.0,1.52M,1.4M,199.94M,,180.58M,0.55%,92.58%,20.74M,9.5,11.72%,10.37%,20.9M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-36.62%,-19.91%,-5.20%,-109.61%,134.72M,0.73,18.20%,17.71M,-24.7M,-49.34M,-0.27,,283.12M,1.42,23.09M,24.53,2.38,0.47,-94.93M,18.43M,Value,02451-1477,Healthcare,79,7,5,"ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.",Waltham,781 895 0600,MA,5,1609372800,1622505600,5,United States,http://www.immunogen.com,86400,5,830 Winter Street,Biotechnology
t-1,IMGN,89570000.0,199942000,,,31388000,,31388000,9738000,46220000,36482000,36482000,,-5703000,,,,0,85798000,49316000,39578000,-5094000,,31388000,31388000,1419460000.0,265502000.0,89570000.0,73606000.0,355072000.0,1950000.0,-1331840000.0,124528000.0,10986000.0,293856000.0,122323000.0,2093000.0,19832000.0,324254000.0,22497000.0,9538000.0,,-20208000.0,-102000.0,97206000.0,5638000.0,97677000.0,105639000.0,8535000.0,532000.0,5009000.0,-13824000.0,-102000.0,-471000.0,201931000.0,en-US,US,EQUITY,True,Delayed Quote,USD,2,NMS,6.18,1630526402,0.12999964,6.04,6.28,5.995,2922641,0,"ImmunoGen, Inc.",PRE,us_market,2.1487544,5.995 - 6.28,6.05,0.0,0.0,40,40,finmb_29794,NasdaqGS,"ImmunoGen, Inc.",USD,1515862,1404971,2.7999997,0.8284023,3.38 - 10.88,-4.7000003,-0.43198532,3.38,10.88,1620649800,1636029000,1636374600,0.09958824,7.0028987,-0.82289886,-0.11750832,-7.6296296,-0.268,-0.81,-0.72,-8.583333,0.471,5.6202855,0.5597143,1235641472,13.121019,15,America/New_York,EDT,-14400000,False,False,1.35,,,10.88,3.38,5.62,7.0,1.52M,1.4M,199.94M,,180.58M,0.55%,92.58%,20.74M,9.5,11.72%,10.37%,20.9M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-36.62%,-19.91%,-5.20%,-109.61%,134.72M,0.73,18.20%,17.71M,-24.7M,-49.34M,-0.27,,283.12M,1.42,23.09M,24.53,2.38,0.47,-94.93M,18.43M,Value,02451-1477,Healthcare,79,7,5,"ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.",Waltham,781 895 0600,MA,5,1609372800,1622505600,5,United States,http://www.immunogen.com,86400,5,830 Winter Street,Biotechnology
t-2,IMGN,-42891000.0,199942000,,,-22374000,,-22374000,10231000,-6496000,-16727000,-16727000,,-5669000,,,,0,18189000,34916000,24685000,-5647000,,-22374000,-22374000,1318591000.0,290843000.0,-42891000.0,60588000.0,247952000.0,1746000.0,-1363228000.0,171619000.0,8570000.0,188217000.0,99821000.0,2089000.0,20055000.0,219327000.0,23235000.0,8913000.0,,722000.0,-771000.0,129000.0,2740000.0,129000.0,-31289000.0,-30647000.0,524000.0,-3695000.0,-8564000.0,-771000.0,-471000.0,119506000.0,en-US,US,EQUITY,True,Delayed Quote,USD,2,NMS,6.18,1630526402,0.12999964,6.04,6.28,5.995,2922641,0,"ImmunoGen, Inc.",PRE,us_market,2.1487544,5.995 - 6.28,6.05,0.0,0.0,40,40,finmb_29794,NasdaqGS,"ImmunoGen, Inc.",USD,1515862,1404971,2.7999997,0.8284023,3.38 - 10.88,-4.7000003,-0.43198532,3.38,10.88,1620649800,1636029000,1636374600,0.09958824,7.0028987,-0.82289886,-0.11750832,-7.6296296,-0.268,-0.81,-0.72,-8.583333,0.471,5.6202855,0.5597143,1235641472,13.121019,15,America/New_York,EDT,-14400000,False,False,1.35,,,10.88,3.38,5.62,7.0,1.52M,1.4M,199.94M,,180.58M,0.55%,92.58%,20.74M,9.5,11.72%,10.37%,20.9M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-36.62%,-19.91%,-5.20%,-109.61%,134.72M,0.73,18.20%,17.71M,-24.7M,-49.34M,-0.27,,283.12M,1.42,23.09M,24.53,2.38,0.47,-94.93M,18.43M,Value,02451-1477,Healthcare,79,7,5,"ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.",Waltham,781 895 0600,MA,5,1609372800,1622505600,5,United States,http://www.immunogen.com,86400,5,830 Winter Street,Biotechnology
t-3,IMGN,-24523000.0,199942000,,,-24298000,,-24298000,9767000,-7896000,-17663000,-17663000,,-6104000,,,,0,15025000,32688000,22921000,-6635000,,-24298000,-24298000,1314586000.0,294251000.0,-24523000.0,55293000.0,269728000.0,1745000.0,-1340854000.0,181116000.0,7591000.0,219506000.0,90879000.0,,20766000.0,241371000.0,15439000.0,12739000.0,2085000.0,1915000.0,-23000.0,423000.0,-3241000.0,653000.0,-27793000.0,-28193000.0,516000.0,1437000.0,-4522000.0,-23000.0,-230000.0,150492000.0,en-US,US,EQUITY,True,Delayed Quote,USD,2,NMS,6.18,1630526402,0.12999964,6.04,6.28,5.995,2922641,0,"ImmunoGen, Inc.",PRE,us_market,2.1487544,5.995 - 6.28,6.05,0.0,0.0,40,40,finmb_29794,NasdaqGS,"ImmunoGen, Inc.",USD,1515862,1404971,2.7999997,0.8284023,3.38 - 10.88,-4.7000003,-0.43198532,3.38,10.88,1620649800,1636029000,1636374600,0.09958824,7.0028987,-0.82289886,-0.11750832,-7.6296296,-0.268,-0.81,-0.72,-8.583333,0.471,5.6202855,0.5597143,1235641472,13.121019,15,America/New_York,EDT,-14400000,False,False,1.35,,,10.88,3.38,5.62,7.0,1.52M,1.4M,199.94M,,180.58M,0.55%,92.58%,20.74M,9.5,11.72%,10.37%,20.9M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-36.62%,-19.91%,-5.20%,-109.61%,134.72M,0.73,18.20%,17.71M,-24.7M,-49.34M,-0.27,,283.12M,1.42,23.09M,24.53,2.38,0.47,-94.93M,18.43M,Value,02451-1477,Healthcare,79,7,5,"ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.",Waltham,781 895 0600,MA,5,1609372800,1622505600,5,United States,http://www.immunogen.com,86400,5,830 Winter Street,Biotechnology
